Publications by authors named "F Morris"

Objective: The IMP-4 carbapenemase is an endemic cause of carbapenem resistance in the Asia-Pacific region. Our aim was to determine the dissemination mechanism of the bla gene.

Methods: Twelve representative Australian IMP-4 clinical isolates from The Alfred Hospital, were characterised using antimicrobial susceptibility testing and genome and plasmid assemblies analysed.

View Article and Find Full Text PDF

Background: Pseudomonas aeruginosa biofilms limit the efficacy of currently available antibacterial therapies and pose significant clinical challenges. Pseudomonal biofilms are complicated further when other markers of persistence such as mucoid and hypermutable phenotypes are present. There is currently a paucity of data regarding the activity of the newer β-lactam/β-lactamase inhibitor combination ceftolozane/tazobactam against P.

View Article and Find Full Text PDF
Article Synopsis
  • * A study was conducted to evaluate a pharmacist-led telehealth MAWV program, comparing satisfaction rates before and after implementing a follow-up protocol through a review of 288 patient charts from 2020 to 2022.
  • * Results indicated that while the initial satisfaction rate of quality metrics was 57.1%, it decreased to 53.3% post-protocol, suggesting that MAWVs can enhance patient care but the follow-up implementation may need optimization.
View Article and Find Full Text PDF

Background: Preoperative anaemia and red blood cell (RBC) transfusions are associated with poorer clinical outcomes. It is unknown whether perioperative RBC transfusions mediate the relationship between preoperative haemoglobin levels and postoperative outcomes.

Methods: This was a prospective observational study among patients aged ≥50 yr undergoing elective major noncardiac surgery from four Swedish hospitals.

View Article and Find Full Text PDF

Objective: The detection/identification of clinically significant antibodies to red cell antigens form the foundation for safe transfusion practices. This study aimed to evaluate the diagnostic performance of commercially available 0.8% reagent red blood cells (RRBCs) in Australia.

View Article and Find Full Text PDF